Seeking Alpha

Cell Therapeutics' (CTIC +5.9%) pacritinib drug showed encouraging anti-tumor activity and good...

Cell Therapeutics' (CTIC +5.9%) pacritinib drug showed encouraging anti-tumor activity and good tolerability in 34 patients with relapsed or refractory lymphoma in a Phase I trial. Pacritinib has already performed well in Phase II studies for patients with myelofibrosis, and the company intends to carry out Phase III trials for this bone-marrow illness. (PR)
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs